Management of Left PCA Territory Infarct with Microhemorrhage

Introduction to Management

The American Heart Association recommends initiating antiplatelet therapy with aspirin 81-325 mg daily as the primary treatment for patients with subacute left PCA territory occipital infarct and intraparenchymal microhemorrhage, while avoiding anticoagulation due to the presence of microhemorrhage 1, 2

Aspirin (81-325 mg daily) is the recommended first-line antiplatelet agent for patients with ischemic stroke in the posterior circulation territory, according to the American College of Cardiology 3, 2
Alternative antiplatelet options include clopidogrel 75 mg daily or the combination of aspirin plus extended-release dipyridamole (25/200 mg twice daily) if aspirin is contraindicated or not tolerated, as suggested by the American Heart Association 3, 2
Dual antiplatelet therapy (aspirin plus clopidogrel) is NOT indicated in this case, as it is only recommended for minor strokes when initiated within 24 hours of symptom onset for up to 90 days, according to the American Stroke Association 1

The presence of intraparenchymal microhemorrhage represents an absolute contraindication to anticoagulation therapy, even though the PCA appears patent, as stated by the International Stroke Society 4
The risk of hemorrhagic expansion with anticoagulation outweighs any potential benefit in preventing recurrent embolism, according to the American College of Cardiology 4

Evaluate for atrial fibrillation with prolonged cardiac monitoring (at least 24 hours), as this would significantly alter long-term management once the microhemorrhage has resolved, as recommended by the American Heart Association 1

Aggressive cardiovascular risk factor management is as important as antiplatelet therapy for preventing recurrent stroke, according to the American College of Cardiology 3, 2
Initiate high-intensity statin therapy regardless of baseline lipid levels for all patients with ischemic stroke, as recommended by the American College of Cardiology 6
Target blood pressure control with antihypertensive medications, aiming for <140/90 mmHg in most patients, according to the American Heart Association 6

Serial neuroimaging is reasonable to monitor for hemorrhagic transformation and resolution of microhemorrhage, as suggested by the American College of Cardiology 2
Repeat MRI with gradient-echo sequences at 3-6 months to reassess the microhemorrhage burden, according to the American Stroke Association 7
Annual noninvasive imaging of vertebral and carotid arteries is reasonable to assess for progression of atherosclerotic disease, as recommended by the American College of Cardiology 2

Do not initiate anticoagulation in the presence of microhemorrhage, even if a cardioembolic source is identified, as stated by the International Stroke Society 4
Do not delay antiplatelet therapy beyond the acute phase, according to the American College of Cardiology 1, 6